Abstract:Background: Infantile hemangiomas (IHs) are the most common benign vascular tumor of infancy. They occur more frequently in female infants. The cause of hemangioma is currently unknown; however, current studies suggested the importance of estrogen (E2) signaling in hemangioma proliferation.Methods: Hemangioma-derived stem cells (HemSCs) were cultured with estrogen for 48-72 h; the cell viability and proliferation were evaluated with the messenger RNA (mRNA) and protein expression levels of fibroblast growth factor 2 (FGF2), vascular endothelial growth factor-A (VEGF-A) and estrogen receptor-alpha (ER-alpha), by application of several in vitro assays, such as methyl thiazolyl tetrazolium (MTT), reverse transcriptase-polymerase chain reaction (RT-PCR), real-time PCR, enzyme-linked immunosorbent assay (ELISA) and Western blotting. Also, the cell population's response to external estrogen was investigated by in vivo experiments. HemSCs and human umbilical vein endothelial cells (HUVECs) were mixed and injected subcutaneously into 20 flank of BALB/ c-nu mice, which were randomly divided into 5 groups based on different E2 treatment doses (0, 0.01, 0.1 and 1 mg, respectively), 0.1 mg dimethyl sulfoxide (DMSO) as control. Each group of mice were treated intramuscularly every week, then 2 and 4 weeks later, the subcutaneous implants were harvested and evaluated the tumor tissues with microvessel density (MVD) assay and immunohistochemistry.Results: The study demonstrated that application of E2 increased the expression of FGF2, VEGF-A, and ER-alpha in HemSCs with the optimal concentration from 10(-9) to 10(-5) M. Two-week treatment of E2 promoted expression of VEGF-A and FGF2 in HemSCs culture. Morphological, histological and immunohistological improvements were observed in vivo using murine IH model in which HemSCs and HUVECs were implanted into BALB/c-nu mice that were post-injected with E2. In the grafts, mean MVD was markedly increased.Conclusion: The results suggested that E2 promotes angiogenesis via combination with ER-alpha to up-regulate the expression of VEGF-A in HemSCs, promoting proliferation of IHs. These findings provide critical insight into the potential mechanisms of E2 action on IHs.

Exosome-derived Mir-196B-5p Facilitates Intercellular Interaction in Infantile Hemangioma Via Down-Regulating CDKN1B

Engineered exosomes for targeted delivery of miR-187-3p suppress the viability of hemangioma stem cells by targeting Notch signaling

MiR-206 Promotes Extracellular Matrix Accumulation and Relieves Infantile Hemangioma Through Targeted Inhibition of DNMT3A

The effect of miR-29a up-regulation on the biological activity of infantile hemangioma endothelial cells

CD133 Selected Stem Cells from Proliferating Infantile Hemangioma and Establishment of an in Vivo Mice Model of Hemangioma

Targeting ESM1 via SOX4 promotes the progression of infantile hemangioma through the PI3K/AKT signaling pathway

Exosomes Derived From Human Induced Pluripotent Stem Cells-Endothelia Cells Promotes Postnatal Angiogenesis In Mice Bearing Ischemic Limbs

Estrogen-Mediated Hemangioma-Derived Stem Cells Through Estrogen Receptor-Alpha For Infantile Hemangioma

LncRNA OIP5-AS1 Promotes the Proliferation of Hemangioma Vascular Endothelial Cells Via Regulating Mir-195-5p/nob1 Axis

Differentiation and Pro-Angiogenic Potential of Infantile Hemangioma Stem Cells

MicroRNA-195-5p Inhibits the Progression of Hemangioma Via Targeting SKI

A novel hsa_circ_0006903 circular RNA promotes tumor development and dendritic cells activated expression in infantile hemangioma

Abstract 17048: Exosomes from Induced Pluripotent Stem Cells Deliver Cardioprotective Mirnas and Prevent Cardiomyocyte Apoptosis in the Ischemic Myocardium

CD146+ mural cells from infantile hemangioma display proangiogenic ability and adipogenesis potential in vitro and in xenograft models

Long non-coding RNA breast cancer-associated transcript 54 sponges microRNA-1269b to suppress the proliferation of hemangioma-derived endothelial cells

Three-Dimensional Microtumor Formation of Infantile Hemangioma-Derived Endothelial Cells for Mechanistic Exploration and Drug Screening

Role Of Endothelial-Mesenchymal Transition In The Tumorigenesis Of Infantile Hemangioma

Epigenetic Silencing of Mir-130A Ameliorates Hemangioma by Targeting Tissue Factor Pathway Inhibitor 2 Through FAK/PI3K/Rac1/mdm2 Signaling.

Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation

MicroRNA‑424 suppresses the proliferation of hemangioma‑derived endothelial cells by targeting VEGFR‑2.

Hypoxia-Induced Cyr61/CCN1 Production in Infantile Hemangioma